Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT05914857
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Registry
-
NCT05914857
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05914857. Randomized; single masking; primary purpose treatment. Start 2023-12-20 (anticipated); primary completion 2025-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients
- Condition
- Prediabetic State
- Condition
- Impaired Fasting Glucose
- Condition
- Impaired Glucose Tolerance
- Intervention (Drug)
- Dapagliflozin 10mg Tab
- Intervention (Behavioral)
- lifestyle interventions
- Lead sponsor
- Yangjin
- Collaborator
- Peking University Third Hospital
Record details
- Record id
cardio:ct-nct05914857- Content hash
22e61c0df8e36f25d6f944e98dbe19404cafd0047f1f1dcfaac5fd70894655f5